Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology

被引：6

作者：

Winter J.N. ^{[1
]}

机构：

[1] Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611

来源：

Current Hematologic Malignancy Reports | 2007年 / 2卷 / 4期

关键词：

Lymphoma; Overall Survival; Clin Oncol; Germinal Center; Intergroup Trial;

D O I：

10.1007/s11899-007-0032-0

中图分类号：

学科分类号：

摘要：

Prognostic markers identify subgroups of patients with similar risk profiles, helping to guide clinical care. The addition of rituximab to conventional anthracycline-based chemotherapy has improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). Studies suggest that rituximab eliminates or modulates the significance of some markers (eg, BCL6 or BCL2), whereas other previously unimportant markers may emerge as significant prognostic indicators in the setting of treatment that now includes rituximab. These changes in the prognostic profile are likely to reflect the impact of rituximab on survival pathways important to some groups of patients with DLBCL but not to other groups, and thereby may provide clues to the underlying biology of the disease. They also identify subgroups of patients likely to benefit most from rituximab therapy and those who seem to garner no advantage from its inclusion in their treatment. Studies of prognostic indicators in the context of modern therapy have the potential to identify new, rational therapeutic targets for this biologically diverse disease. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：235 / 241

页数：6

共 49 条

[1]

Swan Jr F., Velasquez W.S., Tucker S., Et al., A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels, J Clin Oncol, 7, pp. 1518-1527, (1989)

[2]

N Engl J Med, 329, pp. 987-994, (1993)

[3]

Fisher R.I., Gaynor E.R., Dahlberg S., Et al., Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma, N Engl J Med, 328, pp. 1002-1006, (1993)

[4]

Coiffier B., Lepage E., Briere J., Et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 346, pp. 235-242, (2002)

[5]

Feugier P., Van Hoof A., Sebban C., Et al., Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte, J Clin Oncol, 23, pp. 4117-4126, (2005)

[6]

Habermann T.M., Weller E.A., Morrison V.A., Et al., Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma, J Clin Oncol, 24, pp. 3121-3127, (2006)

[7]

Pfreundschuh M., Trumper L., Osterborg A., Et al., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group, Lancet Oncol, 7, pp. 379-391, (2006)

[8]

Pfreundschuh M., Kloess M., Schmits R., Et al., Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract], Blood (ASH Annual Meeting Abstracts), 106, (2005)

[9]

Coiffier B., Feugier P., Mounier P., Et al., Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse, large B-cell lymphoma show good survival in poor risk patients, J Clin Oncol, 25, (2007)

[10]

Sehn L.H., Berry B., Chhanabhai M., Et al., The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP, Blood, 109, pp. 1857-1861, (2007)

← 1 2 3 4 5 →